Loading company
Just reported
From Nephros's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$5.6M
+18% y/y
-6.6% q/q
Guided
—
No guide given
Actual
$0.05
+67% y/y
-55% q/q
Guided
—
No guide given
Actual
$501K
+60% y/y
-59% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Nephros is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.$153.8BA+
MDLNMedline Inc.$51.9BA
ALCAlcon Inc.$36.1BA
BLCOBausch & Lomb Corp$7.5BA-
ATRCAtriCure, Inc.$2.9BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now ABuilt from Nephros, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Grade A
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Nephros, Inc.’s grade history. The other 39 go back to November 2016.
